OCA2 and psoriasis vulgaris: Risankizumab is an IgG1k monoclonal antibody that, like guselkumab, binds the p-19 subunit of IL-23 and is the latest anti-IL-23 drug approved for the treatment of moderate to severe plaque psoriasis in adults.